Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.

Hematology. American Society of Hematology. Education Program - 1 Jan 2007

Mesa Ruben A

Abstract excerpt

The diagnosis and management of the BCR-ABL-negative myeloproliferative disorders (MPDs) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are at an explosive crossroads of scientific investigation and evolving paradigms since the discovery of the tyrosine kinase-activating JAK2V617F mutation in 2005. Additional discovery of relevant molecular lesions (JAK2 exon 12...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Clinical Trials as Topic
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCR gene

Share to JAK2 gene

Share to Mutation

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 18024651
DOI: 10.1182/asheducation-2007.1.355

Genes

JAK2
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.PMID 18024651Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

Recent advances in understanding myelofibrosis and essential thrombocythemiaSemantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Current approaches to challenging scenarios in myeloproliferative neoplasms.Semantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

Genotype-phenotype interactions in the myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.